Nseyo U O, Fontanesi J, Naftulin B N
Urology Section, Veterans Administration Medical Center, Martinez, California.
Urology. 1989 Aug;34(2):76-9. doi: 10.1016/0090-4295(89)90167-2.
Ten patients with hormonally refractory symptomatic metastatic prostate carcinoma underwent palliative hemibody irradiation (HBI). Four of the patients also had had previous irradiation to symptomatic focal sites. Two of the patients underwent upper body HBI with 5 Gy, while 6 patients underwent lower body HBI with 7 Gy. Two patients received sequential lower body HBI followed by upper body HBI. All 10 patients reported subjective pain relief within the immediate forty-eight to ninety-six hours following therapy. The average response lasted four months. Therefore the majority of our patients achieved symptomatic pain relief for the remainder of their lives which averaged five months (range 1.5-12 months). All 10 patients suffered transient but clinically insignificant hematologic toxicity. There was no death or other significant morbidity attributable to the treatment. We conclude that HBI is safe and effective palliation of bone pain in patients who have failed conventional therapy for prostate cancer.
十例激素难治性有症状的转移性前列腺癌患者接受了姑息性半身照射（HBI）。其中四名患者之前也曾对有症状的局部病灶进行过照射。两名患者接受了5 Gy的上身HBI，而六名患者接受了7 Gy的下身HBI。两名患者先接受了顺序性下身HBI，随后接受上身HBI。所有10例患者在治疗后的四十八至九十六小时内均报告主观疼痛缓解。平均缓解持续四个月。因此，我们的大多数患者在其平均为五个月（范围1.5 - 12个月）的余生中实现了症状性疼痛缓解。所有10例患者均出现短暂但临床上无显著意义的血液学毒性。没有因治疗导致的死亡或其他重大发病情况。我们得出结论，对于前列腺癌常规治疗失败的患者，HBI是一种安全有效的缓解骨痛的方法。
